Literature DB >> 22383797

Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.

Laurens P Kil1, Marjolein J W de Bruijn, Menno van Nimwegen, Odilia B J Corneth, Jan Piet van Hamburg, Gemma M Dingjan, Friedrich Thaiss, Guus F Rimmelzwaan, Dirk Elewaut, Dianne Delsing, Pieter Fokko van Loo, Rudi W Hendriks.   

Abstract

On antigen binding by the B-cell receptor (BCR), B cells up-regulate protein expression of the key downstream signaling molecule Bruton tyrosine kinase (Btk), but the effects of Btk up-regulation on B-cell function are unknown. Here, we show that transgenic mice overexpressing Btk specifically in B cells spontaneously formed germinal centers and manifested increased plasma cell numbers, leading to antinuclear autoantibody production and systemic lupus erythematosus (SLE)-like autoimmune pathology affecting kidneys, lungs, and salivary glands. Autoimmunity was fully dependent on Btk kinase activity, because Btk inhibitor treatment (PCI-32765) could normalize B-cell activation and differentiation, and because autoantibodies were absent in Btk transgenic mice overexpressing a kinase inactive Btk mutant. B cells overexpressing wild-type Btk were selectively hyperresponsive to BCR stimulation and showed enhanced Ca(2+) influx, nuclear factor (NF)-κB activation, resistance to Fas-mediated apoptosis, and defective elimination of selfreactive B cells in vivo. These findings unravel a crucial role for Btk in setting the threshold for B-cell activation and counterselection of autoreactive B cells, making Btk an attractive therapeutic target in systemic autoimmune disease such as SLE. The finding of in vivo pathology associated with Btk overexpression may have important implications for the development of gene therapy strategies for X-linked agammaglobulinemia, the immunodeficiency associated with mutations in BTK.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22383797     DOI: 10.1182/blood-2011-12-397919

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  76 in total

1.  Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.

Authors:  Arna Katewa; Yugang Wang; Jason A Hackney; Tao Huang; Eric Suto; Nandhini Ramamoorthi; Cary D Austin; Meire Bremer; Jacob Zhi Chen; James J Crawford; Kevin S Currie; Peter Blomgren; Jason DeVoss; Julie A DiPaolo; Jonathan Hau; Adam Johnson; Justin Lesch; Laura E DeForge; Zhonghua Lin; Marya Liimatta; Joseph W Lubach; Sami McVay; Zora Modrusan; Allen Nguyen; Chungkee Poon; Jianyong Wang; Lichuan Liu; Wyne P Lee; Harvey Wong; Wendy B Young; Michael J Townsend; Karin Reif
Journal:  JCI Insight       Date:  2017-04-06

2.  Increased expression of Bruton's tyrosine kinase in peripheral blood is associated with lupus nephritis.

Authors:  Wei Kong; Wei Deng; Yue Sun; Saisai Huang; Zhuoya Zhang; Bingyu Shi; Weiwei Chen; Xiaojun Tang; Genhong Yao; Xuebing Feng; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2017-06-14       Impact factor: 2.980

3.  Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma.

Authors:  Iván Fernández-Vega; Luis M Quirós; Jorge Santos-Juanes; María Pane-Foix; Teresa Marafioti
Journal:  Virchows Arch       Date:  2014-11-30       Impact factor: 4.064

Review 4.  Long-Range Regulation of V(D)J Recombination.

Authors:  Charlotte Proudhon; Bingtao Hao; Ramya Raviram; Julie Chaumeil; Jane A Skok
Journal:  Adv Immunol       Date:  2015-08-20       Impact factor: 3.543

Review 5.  BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Authors:  M Spaargaren; M F M de Rooij; A P Kater; E Eldering
Journal:  Oncogene       Date:  2014-06-23       Impact factor: 9.867

6.  Bruton's tyrosine kinase promotes persistence of mature anti-insulin B cells.

Authors:  Rachel H Bonami; Allison M Sullivan; James B Case; Hannah E Steinberg; Kristen L Hoek; Wasif N Khan; Peggy L Kendall
Journal:  J Immunol       Date:  2014-01-22       Impact factor: 5.422

Review 7.  The role of tyrosine kinases in systemic lupus erythematosus and their potential as therapeutic targets.

Authors:  Wen-Hai Shao; Philip L Cohen
Journal:  Expert Rev Clin Immunol       Date:  2014-03-29       Impact factor: 4.473

Review 8.  When the balance is broken: X-linked gene dosage from two X chromosomes and female-biased autoimmunity.

Authors:  Camille M Syrett; Montserrat C Anguera
Journal:  J Leukoc Biol       Date:  2019-05-24       Impact factor: 4.962

9.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

Review 10.  Current and future therapies for primary Sjögren syndrome.

Authors:  Raphaèle Seror; Gaetane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2021-06-29       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.